HK Stock Market Move | HENLIUS (02696) rose nearly 5% in the afternoon. HENLIUS TCE platform data makes its debut at 2026 AACR.

HENLIUS (02696) rose nearly 5% in the afternoon, rising 3.91% to HK$82.35 at the time of publication, with a turnover of HK$617.294 million. On the news front, HENLIUS recently unveiled its preclinical research data on the novel CD3CD28STEAP1-targeted triple-specific T cell engager (TCE) HLX3902 at the 2026 American Association for Cancer Research (AACR) Annual Meeting in poster form for the first time. The company is continuing to advance the platform's expansion into more "immunologically cold" solid tumors, with over 5 early innovative molecules incubated based on the platform. Western previously released a research report, forecasting the company's revenue for 2026-2028 to be RMB 7.397/8.039/9.535 billion, with year-on-year growth of 11.0%/8.7%/18.6%. The company's innovative layout has shown significant effects, with many catalysts such as clinical data reading, potential BD expectations, as well as the increase in performance from the overseas market for biosimilar drugs. The "buy" rating is maintained.